Search research articles
Contact Us
Filters
Showing results (51-60 of 65) with videos related to
Page
of 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 12, 2018
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach
R Galot, C Le Tourneau, J Guigay, et al.
ESMO Open
|
August 25, 2023
Corrigendum to 'Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up': [ESMO Open 7(6):100602, December 2022]
C van Herpen, V Vander Poorten, A Skalova, et al.
ESMO Open
|
December 25, 2022
Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up
C van Herpen, V Vander Poorten, A Skalova, et al.
Oral Oncology
|
November 5, 2023
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
K J Harrington, E E W Cohen, D Soulières, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 5, 2012
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
E Seront, S Rottey, B Sautois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 13, 2005
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study
J-P Machiels, L Duck, B Honhon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2007
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer
J-P Machiels, C Sempoux, P Scalliet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2018
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)
J-P Machiels, P Bossi, J Menis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
P M Clement, T Gauler, J P Machiels, et al.
ESMO Open
|
May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
R Galot, C Le Tourneau, L Licitra, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 65) with videos related to
Sort By:
Page
of 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 12, 2018
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach
R Galot, C Le Tourneau, J Guigay, et al.
ESMO Open
|
August 25, 2023
Corrigendum to 'Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up': [ESMO Open 7(6):100602, December 2022]
C van Herpen, V Vander Poorten, A Skalova, et al.
ESMO Open
|
December 25, 2022
Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up
C van Herpen, V Vander Poorten, A Skalova, et al.
Oral Oncology
|
November 5, 2023
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
K J Harrington, E E W Cohen, D Soulières, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 5, 2012
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
E Seront, S Rottey, B Sautois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 13, 2005
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study
J-P Machiels, L Duck, B Honhon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2007
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer
J-P Machiels, C Sempoux, P Scalliet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2018
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)
J-P Machiels, P Bossi, J Menis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
P M Clement, T Gauler, J P Machiels, et al.
ESMO Open
|
May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
R Galot, C Le Tourneau, L Licitra, et al.
Page
of 7